Home

Justin J. File

CIK 1726277 · CEO, CFO and Secretary · last filed 2026-02-12

Justin J. File is a CEO, CFO and Secretary who has filed 31 SEC Form 4 insider transactions across 4 companies since 2018. The most recent filing, for LITS, was dated Feb 12, 2026. Across all open-market trades the lifetime net is −$48.0K, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

4

Total Filings

31

Lifetime Open-Market Net

-$48.0K

Filer Profile

Reported Address
C/O MEI PHARMA, INC.
9920 PACIFIC HEIGHTS BLVD., SUITE 150
SAN DIEGO, CA 92121
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LITS CEO, CFO and Secretary — $1.06 — $0 3 2026-02-12
Lite Strategy, Inc. (MEIP) Delisted Secretary, Acting CEO & CFO — $3.20 — $0 1 2025-07-17
Evofem Biosciences, Inc. (EVFM) Delisted Chief Financial Officer 433 $0.01 $4 -$48.0K 26 2022-02-23
Evofem Biosciences, Inc. (NEOT) Delisted Chief Financial Officer — — — $0 1 2018-01-18

Recent Filings

31 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-02-12 LITS Grant (A) — $0 EDGAR
2025-11-20 LITS Grant (A) — $0 EDGAR
2025-11-18 LITS Grant (A) — $0 EDGAR
2025-07-17 Lite Strategy, Inc. (MEIP) Delisted Grant (A) — $0 EDGAR
2022-02-23 Evofem Biosciences, Inc. (EVFM) Delisted Grant (A) +450,000 $0 EDGAR
2022-01-04 Evofem Biosciences, Inc. (EVFM) Delisted Disp (D) −120,000 $0 EDGAR
2021-12-20 Evofem Biosciences, Inc. (EVFM) Delisted Buy (P) +40,594 $15.0K EDGAR
2021-06-10 Evofem Biosciences, Inc. (EVFM) Delisted Buy (P) +24,500 $25.2K EDGAR
2021-05-21 Evofem Biosciences, Inc. (EVFM) Delisted Tax (F) −42,280 -$36.4K EDGAR
2021-02-03 Evofem Biosciences, Inc. (EVFM) Delisted Grant (A) +200,000 $0 EDGAR
Showing 1–10 of 31
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.